195 related articles for article (PubMed ID: 11393573)
1. Decreased bone mineral density and bone formation markers shortly after diagnosis of clinical type 1 diabetes mellitus.
Gunczler P; Lanes R; Paoli M; Martinis R; Villaroel O; Weisinger JR
J Pediatr Endocrinol Metab; 2001 May; 14(5):525-8. PubMed ID: 11393573
[TBL] [Abstract][Full Text] [Related]
2. Decreased lumbar spine bone mass and low bone turnover in children and adolescents with insulin dependent diabetes mellitus followed longitudinally.
Gunczler P; Lanes R; Paz-Martinez V; Martins R; Esaa S; Colmenares V; Weisinger JR
J Pediatr Endocrinol Metab; 1998; 11(3):413-9. PubMed ID: 11517957
[TBL] [Abstract][Full Text] [Related]
3. The effect of short- and long-term growth hormone treatment on bone mineral density and bone metabolism of prepubertal children with idiopathic short stature: a 3-year study.
Lanes R; Gunczler P; Esaa S; Weisinger JR
Clin Endocrinol (Oxf); 2002 Dec; 57(6):725-30. PubMed ID: 12460321
[TBL] [Abstract][Full Text] [Related]
4. Prediction of bone mass in renal hyperparathyroidism by newly developed bone metabolic markers: evaluation of serum levels of carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen and carboxy-terminal propeptide of type I procollagen.
Katagiri M; Fukunaga M; Ohtawa T; Harada T
World J Surg; 1996 Sep; 20(7):753-6; discussion 756-7. PubMed ID: 8678946
[TBL] [Abstract][Full Text] [Related]
5. Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults.
Välimäki MJ; Salmela PI; Salmi J; Viikari J; Kataja M; Turunen H; Soppi E
Eur J Endocrinol; 1999 Jun; 140(6):545-54. PubMed ID: 10377504
[TBL] [Abstract][Full Text] [Related]
6. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty.
Boot AM; De Muinck Keizer-Schrama S; Pols HA; Krenning EP; Drop SL
J Clin Endocrinol Metab; 1998 Feb; 83(2):370-3. PubMed ID: 9467543
[TBL] [Abstract][Full Text] [Related]
7. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome.
Hermus AR; Smals AG; Swinkels LM; Huysmans DA; Pieters GF; Sweep CF; Corstens FH; Kloppenborg PW
J Clin Endocrinol Metab; 1995 Oct; 80(10):2859-65. PubMed ID: 7559865
[TBL] [Abstract][Full Text] [Related]
8. Impaired development of bone mineral density during chemotherapy: a prospective analysis of 46 children newly diagnosed with cancer.
Arikoski P; Komulainen J; Riikonen P; Parviainen M; Jurvelin JS; Voutilainen R; Kröger H
J Bone Miner Res; 1999 Dec; 14(12):2002-9. PubMed ID: 10620058
[TBL] [Abstract][Full Text] [Related]
9. Effects of 12 months of recombinant growth hormone therapy on parameters of bone metabolism and bone mineral density in patients on chronic hemodialysis.
Kotzmann H; Riedl M; Pietschmann P; Schmidt A; Schuster E; Kreuzer S; Kainberger F; Frisch H; Geyer G; Hörl WH; Mayer G; Luger A
J Nephrol; 2004; 17(1):87-94. PubMed ID: 15151263
[TBL] [Abstract][Full Text] [Related]
10. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
[TBL] [Abstract][Full Text] [Related]
11. Bone mineral density of the spine and femur in healthy Saudi females: relation to vitamin D status, pregnancy, and lactation.
Ghannam NN; Hammami MM; Bakheet SM; Khan BA
Calcif Tissue Int; 1999 Jul; 65(1):23-8. PubMed ID: 10369729
[TBL] [Abstract][Full Text] [Related]
12. Currently used growth-promoting treatment of children results in normal bone mass and density. A prospective trial of discontinuing growth hormone treatment in adolescents.
Fors H; Bjarnason R; Wirént L; Albertsson-Wikland K; Bosaeust L; Bengtsson BA; Johannsson G
Clin Endocrinol (Oxf); 2001 Nov; 55(5):617-24. PubMed ID: 11894973
[TBL] [Abstract][Full Text] [Related]
13. Alterations in bone turnover and impaired development of bone mineral density in newly diagnosed children with cancer: a 1-year prospective study.
Arikoski P; Komulainen J; Riikonen P; Voutilainen R; Knip M; Kröger H
J Clin Endocrinol Metab; 1999 Sep; 84(9):3174-81. PubMed ID: 10487683
[TBL] [Abstract][Full Text] [Related]
14. Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs.
Välimäki MJ; Tiihonen M; Laitinen K; Tähtelä R; Kärkkäinen M; Lamberg-Allardt C; Mäkelä P; Tunninen R
J Bone Miner Res; 1994 May; 9(5):631-7. PubMed ID: 8053391
[TBL] [Abstract][Full Text] [Related]
15. Low-dose estrogen combined oral contraceptives may negatively influence physiological bone mineral density acquisition during adolescence.
Cibula D; Skrenkova J; Hill M; Stepan JJ
Eur J Endocrinol; 2012 Jun; 166(6):1003-11. PubMed ID: 22436400
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of cross-linked N-telopeptides and aminoterminal propeptides of type I collagen indicate low bone mineral density in elderly women.
Scariano JK; Glew RH; Bou-Serhal CE; Clemens JD; Garry PJ; Baumgartner RN
Bone; 1998 Nov; 23(5):471-7. PubMed ID: 9823455
[TBL] [Abstract][Full Text] [Related]
17. The levels of bone turnover markers 25(OH)D and PTH and their relationship with bone mineral density in postmenopausal women in a suburban district in China.
Gao C; Qiao J; Li SS; Yu WJ; He JW; Fu WZ; Zhang ZL
Osteoporos Int; 2017 Jan; 28(1):211-218. PubMed ID: 27468899
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic efficacy of serum cross-linked N-telopeptide (NTx) and aminoterminal procollagen extension propeptide (PINP) measurements for identifying elderly women with decreased bone mineral density.
Scariano JK; Garry PJ; Montoya GD; Duran-Valdez E; Baumgartner RN
Scand J Clin Lab Invest; 2002; 62(3):237-43. PubMed ID: 12088343
[TBL] [Abstract][Full Text] [Related]
19. Bone mineral density and alterations of bone metabolism in children and adolescents with type 1 diabetes mellitus.
Karagüzel G; Akçurin S; Ozdem S; Boz A; Bircan I
J Pediatr Endocrinol Metab; 2006 Jun; 19(6):805-14. PubMed ID: 16886588
[TBL] [Abstract][Full Text] [Related]
20. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization.
Colao A; Di Somma C; Loche S; Di Sarno A; Klain M; Pivonello R; Pietrosante M; Salvatore M; Lombardi G
Clin Endocrinol (Oxf); 2000 Mar; 52(3):319-27. PubMed ID: 10718830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
